Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Turalio First FDA-Approved Systemic Therapy for Tenosynovial Giant-Cell Tumor

Web Exclusives - FDA Updates

On August 2, 2019, the FDA approved pexidartinib (Turalio; Daiichi Sankyo) capsules, a kinase inhibitor, for adults with symptomatic tenosynovial giant-cell tumor (TGCT), which is associated with severe morbidity or functional limitations, who are not candidates for surgery. Pexidartinib is the first systemic therapy approved for patients with TGCT. The FDA granted pexidartinib a priority review and breakthrough therapy and orphan drug designations.

The FDA approval was based on the international, multicenter, randomized (1:1), double-blind, placebo-controlled clinical trial of 120 patients with TGCT that could not be removed by surgery. The primary end point was durable overall response rate (ORR), as determined by an independent review committee at week 25.

Patients were randomized in a 1:1 ratio to pexidartinib or to placebo. After 25 weeks, the ORR was 38% (95% confidence interval, 27-50), including 15% complete responses and 23% partial responses, with pexidartinib versus no responses with placebo (P <.0001). Overall, 22 patients who responded to pexidartinib therapy maintained the response for ≥6 months. In addition, 13 patients maintained the response for ≥12 months.

Patients with enough data had significant improvement in the range of motion of the affected joint at week 25 with pexidartinib versus placebo.

The most common side effects with pexidartinib were increased lactate dehydrogenase, increased aspartate aminotransferase, hair color changes, increased alanine aminotransferase, and increased cholesterol. Pexidartinib was approved with a boxed warning about the risk for fatal liver injury; the drug is only available through a Risk Evaluation and Mitigation Strategy program.

Related Items
Recent Cancer Drugs Approved by the FDA
JHOP - February 2020 Vol 10, No 1 published on February 19, 2020 in FDA Updates
FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib
Web Exclusives published on February 4, 2020 in FDA Updates, In the News, Lung Cancer, Thyroid Cancer
Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma
Web Exclusives published on January 28, 2020 in FDA Updates, In the News, Sarcoma
FDA Grants Approval to Avapritinib for Patients with GIST
Web Exclusives published on January 13, 2020 in FDA Updates, Gastrointestinal Cancers, In the News, Rare Cancers
Recap of FDA Drug Approvals in 2019
Web Exclusives published on January 7, 2020 in FDA Updates, In the News
December 19, 2019 - FDA News & Updates
Web Exclusives published on December 17, 2019 in Drug Updates, FDA Updates
Regenerative Medicine Advanced Therapy Designation Granted to ADP-A2M4 for Synovial Sarcoma
Web Exclusives published on December 11, 2019 in FDA Updates, In the News, Sarcoma
FDA Grants Priority Review to Keytruda for Patients with High-Risk, Non–Muscle-Invasive Bladder Cancer
Web Exclusives published on December 3, 2019 in Bladder Cancer, FDA Updates, Immunotherapy
Inrebic Receives FDA Approval for Adults with Myelofibrosis
Web Exclusives published on December 2, 2019 in FDA Updates
FDA Approved Erleada for Metastatic Castration-Sensitive Prostate Cancer
Web Exclusives published on December 2, 2019 in FDA Updates
Last modified: October 29, 2019